BMYMP News and Press, Bristol-Myers Squibb $2Pr From 01/18/23

Summary While foreign competitors Novartis and Roche scored better than Bristol Myers in my recent pipeline analysis, BMY is the best US option. This article will revisit the metrics that allowed BMY to beat competitors such as Pfizer and Merck. With a combination of a slow prior fi...

Summary In 2015, I started publishing updates regarding my dividend growth portfolio, and I keep doing so every quarter. This is part of being transparent with my readers, so they can see what I hold and its correlation with my writing. This article summarizes Q4 of 2022 and focuses...

Summary Relying on the high-flyers of tomorrow is a strategy that is rarely successful, emotionally taxing, and not scalable. In this article, I will explain, at the example of five companies, the advantages of a dividend growth strategy. I will highlight why the strategy outperform...

Summary IGA generated a strong yield and has been able to achieve its objective of generating stable current income. The average annual total return also is quite high. IGA invests in stocks in ICT, financial, industrial, and healthcare sectors. These sectors in my view have maximum gro...

Summary Fidelity Dividend ETF for Rising Rates ETF invests in dividend stocks that should profit from rising rates. It is better than the S&P 500 regarding valuation and quality metrics. Return and dividend growth since inception are unattractive. Despite rising rates, the f...

Summary The pipeline is the heart of a drug discovery company. As such, analyzing the health of a pipeline can lead to suggestions about future performance. This article will analyze the 10 largest pharmaceuticals and determine where the strongest pipelines lie. Introducti...

Bristol-Myers Squibb Co. (BMY) J.P. Morgan 41st Annual Healthcare Conference Call January 9, 2023 10:30 ET Company Participants Chris Boerner - Chief Commercial Officer Conference Call Participants Christopher Schott - J.P. Morgan Presentation Christo...

Summary Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half. Biotechnology should be favorably positioned relative to the market if the economy slips into a recession. Biotech fortunes near term are to be determined by the ...

Summary Big pharma performed well in 2022, but the time to trim is drawing close. As a more diversified investment, I believe former parent company of Merck & Co, Merck KGaA offers a better long-term investment. With diversification and strong fundamentals, Merck KGaA is a far b...

Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. Introduction The Dividend Champions list is a m...